Alexion Looks To Broaden Complement Inhibitor Market With Next-Generation Ultomiris
Executive Summary
Positive late-stage clinical results involving Ultomiris in a second potential indication suggest Alexion is on the right track to develop new ultra-rare disease therapies with significant commercial potential.
You may also be interested in...
Alexion’s Phase III Data Position Ultomiris For Expansion Into Myasthenia Gravis
As its acquisition by AstraZeneca moves toward closure, Alexion plans to file the Soliris follow-on for generalized myasthenia gravis in the US, EU and Japan. But potential competition awaits in the C5 inhibitor and FcRn antagonist classes.
Keeping Track: Industry Beefs Up 2020 Review Pipeline With Submissions Galore
The latest drug development news and highlights from our US FDA Performance Tracker.
EU Ultomiris Approval Rounds Off A Good Week For Alexion’s Complement Franchise
A first EU approval for Ultomiris added to a label expansion for Soliris in the US made for a good seven days for Alexion’s C5 product portfolio.